Allosteric enhancers of A1 adenosine receptors: State of the art and new horizons for drug development

Current Medicinal Chemistry

Volumn 17, Issue 30, 2010, Pages 3488-3502

  Romagnoli, R ^a   Baraldi, P G ^a   Tabrizi, M A ^a   Gessi, S ^a   Borea, P A ^a   Merighi, S ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

A1 adenosine receptor; Allosteric modulators; Enhancer; Neuropatic pain; Neuroprotection

Indexed keywords

2 AMINO 3 (3 CHLOROBENZOYL) 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 2 AMINO 6 BENZYL 3 (4 CHLOROBENZOYL) 4,5,6,7 TETRAHYDROTHIENO[2,3 C]PYRIDINE; 4 AMINOBUTYRIC ACID A RECEPTOR; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENYLATE CYCLASE; CALCIUM CHANNEL; G PROTEIN COUPLED RECEPTOR; INOSITOL PHOSPHATE; POTASSIUM CHANNEL; UNCLASSIFIED DRUG; 2 AMINOTHIAZOLE; 2-AMINOTHIAZOLE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ACTIVITY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INFLAMMATION; SECOND MESSENGER; ALLOSTERISM; CHEMISTRY; METABOLISM; REVIEW;

ALLOSTERIC REGULATION; HUMANS; RECEPTOR, ADENOSINE A1; THIAZOLES; THIOPHENES;

EID: 77957961698     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710792927831     Document Type: Article

References (66)

1. Leach, K.; Sexton, P.M.; Christopoulos, A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci., 2007, 28, 382-389.
2. Milligan, G.; Smith, N.J. Allosteric modulation of heterodimeric G protein-coupled receptors. Trends Pharmacol. Sci., 2007, 28, 615-620.
3. Schwartz, T.W.; Holst, B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol. Sci., 2007, 28, 366-373.
4. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov., 2002, 1, 198-210.
5. Figler, H.; Olsson, R.A.; Linden, J. Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. Mol. Pharmacol., 2003, 64, 1557-1564.
6. De Lean, A.; Stadel, J.M.; Lefkowitz, R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled -adrenergic receptor. J. Biol. Chem., 1980, 255, 7108-7117
7. Valant, C.; Sexton, P.M.; Christopoulos, A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol. Interv., 2009, 9, 125-135
8. Mohr, K.; Tränkle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational design of dualsteric GPCR ligands: quests and promise. Br. J. Pharmacol., 2010, 159, 997-1008.
9. Zimmermann, H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmied. Arch. Pharmacol., 2000, 362, 299-309.
10. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev., 1998, 50, 413-492.
11. van Calker, D.M.; Muller, M.; Hamprecht, B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem., 1979, 33, 999-1005.
12. Rogel, A.; Bromberg, Y.; Sperling, O.; Zoref-Shani, E. Phospholipase C is involved in the adenosine-activated signal transduction pathway conferring protection against iodoacetic acid-induced injury in primary rat neuronal cultures. Neurosi. Lett., 2005, 373, 218-221.
13. Schulte, G.; Fredholm, B.B. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal., 2003, 15, 813-827.
14. Eisenach, J.C.; Hood D.D.; Curry, R. Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology, 2002, 96, 29-34
15. Fredholm, B.B.; Bättig, K.; Holmen, J.; Nehlig, A.; Zvartau, E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev., 1999, 51, 83-133.
16. Mubagwa, K.; Flameng, W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc. Res., 2001, 52, 25-39.
17. Russo, C.; Arcidiacono, G.; Polosa R. Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma. Fundam. Clin. Pharmacol., 2006, 20, 9-19.
18. Driver, A.G.; Kukoly, C.A.; Ali, S.; Mustafa, S.J. Adenosine in bronchoalveolar lavage fluid in asthma. Am. Rev. Respir. Dis., 1993, 148, 91-97.
19. Wilson, C.N.; Batra, V.K. Lipopolysaccharide binds to and activates A(1) adenosine receptors on human pulmonary artery endothelial cells. J. Endotoxin. Res., 2002, 8, 263-271.
20. Schutte, F.; Burgdorf, C.; Richardt, G.; Kurz, T. Adenosine A1 receptor-mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase. Can. J. Physiol. Pharmacol., 2006, 84, 573-577.
21. Liang B.T. Protein kinase C-mediated preconditioning of cardiac myocytes: role of adenosine receptor and KATP channel. Am. J. Physiol. Heart Circ. Physiol., 1997, 273, H847-853.
22. Shneyvays, V.; Leshem, D.; Zinman, T.; Mamedova, L.K.; Jacobson, K.A.; Shainberg, A. Role of adenosine A1 and A3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. Am. J. Physiol. Heart Circ. Physiol., 2005, 288, H2792-2801.
23. Solenkova, N.V.; Solodushko, V.; Cohen, M.V.; Downey, J.M. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H441-449.
24. Yldiz, G.; Demiryurek, A.T.; Gumusel, B.; Lippton, H. Ischemic preconditioning modulates ischemia-reperfusion injury in the rat lung: role of adenosine receptors. Eur. J. Pharmacol., 2007, 556, 144-150.
25. Grenz, A.; Zhang, H.; Eckle, T.; Mittelbronn, M.; Wehrmann, M.; Kohle, C.; Kloor, D.; Thompson, L. F.; Osswald, H.; Eltzschig, H. K. Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. J. Am. Soc. Nephrol., 2007, 18, 833-845.
26. Welch, W.J. Adenosine A1 receptor antagonists in the kidney: effects in fluid-retaining disorders. Curr. Opin. Pharmacol., 2002, 2,165-170.
27. Baraldi, P.G.; Tabrizi, M.A.; Gessi, S.; Borea, P.A. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem. Rev., 2008, 108, 238-263.
28. a) Göblyös, A.; IJzerman, A.P. Allosteric modulation of adenosine receptors. Purinergic Signal., 2009, 5, 51-61
29. Baraldi, P.G.; Iaconinoto, M.A.; Moorman, A.R.; Carrion, M. D.; Cara, C.L.; Preti, D.; Lopez, O.C.; Fruttarolo, F.; Tabrizi, M.A.; Romagnoli, R. Allosteric enhancers for A1 adenosine receptor. Mini Rev. Med. Chem., 2007, 7, 559-569
30. Gao, Z.-G.; Kim, S.-K.; IJzerman, A.P.; Jacbson, K.A. Allosteric modulation of the adenosine family of receptors. Mini Rev. Med. Chem., 2005, 5, 545-553
31. Baraldi, P.G.; Moorman, A.R.; Tabrizi, M.A.; Pavani, M.G.; Romanoli, R. Allosteric modulators for the A1-adenosine receptor. Expert Opin. Ther. Pat., 2004, 14, 71-79
32. IJzerman, A.P.; Kouronakis, A.; van der Klein, P. Allosteric modulators of G protein-coupled receptors. Il Farmaco, 2001, 56, 67-71.
33. Bruns, R.F.; Fergus, J.H. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol., 1990, 38, 939-949.
34. Bruns, R. F.; Fergus, J. H.; Coughenour, L.L.; Courtland, G.G.; Pugsley, T.A.; Dodd, J.H.; Tinney, F.J. Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2amino-3benzoylthiophenes. Mol. Pharmacol., 1990, 38, 950-958.
35. Musser, B.; Mudumbi, R.V.; Liu, J.; Olson, R.D.; Vestal, R.E. Adenosine A1 receptor-dependent and-independent effects of the allosteric enhancer PD 81,723. J. Pharmacol. Exp. Ther., 1999, 288, 446-454
36. Bhattacharya, S.; Linden, J. Effects of long-term treatment with the allosteric enhancer, PD-81,723, on Chinese hamster ovary cells expressing recombinant human A1 adenosine receptors. Mol. Pharmacol., 1996, 50, 104-111.
37. Janusz, C.A.; Berman R.F: The adenosine binding enhancer, PD 81,723 inhibits epileptiform bursting in the hippocampal brain slice. Brain Res., 1993, 619, 131-136.
38. Amoah-Apraku, B.; Xu, J.; Lu, J J.Y.; Pelleg, A.; Bruns, R.F.; Belardinelli, L: Selective potentiation by an A1 adenosine receptor enhancer of the negative dromotropic action of adenosine in the guinea pig heart. J. Pharmacol. Exp. Ther., 1993, 266, 611-617.
39. Bhattacharaya, S.; Linden, J. The allosteric enhancer, PD 81,723, stabilizes human A1 adenosine receptor coupling to G proteins. Biochim. Biophys. Acta, 1995, 1265, 15-21
40. Bhattacharaya, S.; Linden, J. Effects of long-term treatment with the allosteric enhancer, PD81,723, on Chinese hamster ovary cells expressing recombinant human A1 adenosine receptors. Mol. Pharmacol., 1996, 50, 104-111
41. Kourounakis, A.P.; Visser, C.; De Groote, M.; IJzerman, A.P. Differential effects of the allosteric enhancer (2amino-4,5-dimethyl-thienyl)][3-(trifluoromethyl)phenyl]methanone (PD 81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. Biochem. Pharmacol., 2001, 61, 137-144.
42. Mudumbi, R.V.; Montamat, S.C.; Bruns, R.F.; Vestal, R.E. Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor. Am. J. Physiol., 1993, 264, H1017-H1022.
43. Mizamura, T.; Auchampach, J.A.; Linden, J.; Bruns, R.F.; Gross, G.J. PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ. Res., 1996, 79, 415-423.
44. Baraldi, P.G.; Zaid, A.N.; Lampronti, I.; Fruttarolo, F.; Pavani, M.G.; Tabrizi, M.A.; Shryock, J.C.; Leung, E.; Romagnoli, R. Synthesis and biological effects of a new series of 2-amino-3benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. Bioorg. Med. Chem. Lett., 2000, 10, 1953-1957.
45. van der Klein, P.A.M.; Kourounakis, A.P.; IJzerman, A.P. Allosteric modulation of the adenosine A1 receptor: synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding, J. Med. Chem., 1999, 42, 3629-3635.
46. Kourounakis, A.P.; van der Klein, P.A.M.; IJzerman, A.P. Elucidation of stucture-activity relationships of 2-amino-3benzoylthiophenes:study of their allosteric enhanceing vs. antagonistic activity on adenosine A1 receptors. Drug Dev. Res., 2000, 49, 227-237.
47. Tranberg, C.E.; Zickgraf, A.; Giunta, B.N.; Luetjens, H.; Figler, H.; Murphree, L.J.; Falke, R.; Fleischer, H.; Linden, J.; Scammells, P.J.; Olsson, R. A. 2-Amino-3-aroyl-4,5-alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors. J. Med. Chem., 2002, 45, 382-389.
48. Luetjens, H.; Zickgraf, A.; Figler, H.; Linden, J.; Olsson, R.A.; Scammells, P.J. 2-Amino-3-benzoylthiophene allosteric enhancers of A1 adenosine agonist binding: new 3, 4-, and 5-modifications. J. Med. Chem., 2003, 46, 1870-1877.
49. For a complete pharmacological characterization of T-62 see: a) Childers, S.R.; Li, X.; Xiao, R.; Eisanach, J.C. Allosteric modulation of adenosine A1 receptor coupling to G-proteins in brain. J. Neurochem., 2005, 93, 715-723
50. Li, X.; Conklin, D.; Ma, W.; Zhu, X. Eisenach, J.C. Spinal noradrenergic activation mediates allodynia reduction from an allosteric adenosine modulator in a rat model of neuropathic pain. Pain 2002, 97, 117-125
51. Li, X.; Conklin, D.; Pan, H.-L.; Eisenach, J.C. Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism. J. Pharmacol. Exp. Ther., 2003, 305, 950-955
52. ClinicalTrials.gov Identifier: NCT00809679.
53. Baraldi, P.G.; Pavani, M.G.; Shryock J.C.; Moorman, A.R.; Iannotta, V.; Borea, P.A.; Romagnoli, R. Synthesis of 2-amino-3heteroaroylthiophenes and evaluation of their activity as potential allosteric enhancers at the human A1 receptor. Eur. J. Med. Chem., 2004, 39, 855-865.
54. Baraldi, P.G.; Romagnoli, R.; Pavani, M.G.; Nuñez, M.C.; Tabrizi, M.A.; Shryock, J.C.; Leung, E.; Moorman, A.R.; Uluoglu, C.; Iannotta, V.; Merighi, S.; Borea, P.A. Synthesis and biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptor. J. Med. Chem., 2003, 46, 794-809
55. Nikolakopoulos, G.; Figler, H.; Linden, J.; Scammells, P.J. Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers. Bioorg. Med. Chem., 2006, 14, 2358-2365.
56. Figler, H.; Olsson, R.A.; Linden, J. Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract guanine nucleotide effects on agonist binding. Mol. Pharmacol., 2003, 64, 1557-1564.
57. Aurelio, L.; Valant, C.; Figler, H.; Flynn, B.L.; Linden, J.; Sexton, P.M.; Christopoulos, A.; Scammells, P.J. 3and 6infstituted 2-amino-4,5,6,7-tetrahydro[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. Bioorg. Med. Chem., 2009, 17, 7353-7361
58. Valant, C.; Aurelio, L.; Urmaliya, V.B.; White, P.; Scammells, P.J.; Sexton, P.M.; Christopoulos, A. Delineating the mode of action of adenosine A1 receptor allosteric modulators. Mol Pharmacol., 2010, in press.
59. Aurelio, L.; Valant, C.; Flynn, B.L.; Sexton, P.M.; Christopoulos, A.; Scammells, P.J. Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-infstituted 2-amino-3-benzoylthiophenes. J. Med. Chem., 2009, 52, 4543-4547.
60. Aurelio, L.; Figler, H.; Flynn, B.L.; Linden, J.; Scammells, P.J. 5infstituted 2-aminothiophenes as A1 adenosine receptor allosteric enhancers. Bioorg. Med. Chem., 2008, 16, 1319-1327.
61. Romagnoli, R.; Baraldi, P.G.; Moorman, A.R.; Iaconinoto, M.A.; Carrion, M.D.; Cara, C.L., Tabrizi, M.A.; Preti, D.; Fruttarolo, F.; Baker, S.P.; Varani, K.; Borea, P.A. Microwave-assisted synthesis of thieno[2,3-c]pyridine derivatives as a new series of allosteric enhancers at the adenosine A1 receptor. Bioorg. Med. Chem. Lett., 2006, 16, 5530-5533.
62. Romagnoli, R.; Baraldi, P.G.; Carrion, M.D.; Lopez-Cara, C.; Cruz-Lopez, O.; Iaconinoto, M.A.; Preti, D.; Shryock, J.C.; Moorman, A.R.; Vincenzi, F.; Varani, K.; Borea, P.A. Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N(infstituted) piperazin-1-yl]thiophenes as Potent allosteric enhancers of the A1 adenosine receptor receptor. J. Med. Chem., 2008, 51, 5875-5879.
63. Aumann, K.M.; Scammells, P.J.; White, J.M.; Schiesser, C.H. On the stability of aminoselenophene-3-carboxylates: potential dualacting selenium-containing allosteric enhancers of A1 adenosine receptor binding. Org. Biomol. Chem., 2007, 5, 1276-1281.
64. Chordia, M.D.; Murphree, L.J.; Macdonald, T.L.; Linden, J.; Olsson, R. A. 2-Aminothiazoles: A new class of agonist allosteric enhancers of A1 adenosine receptors. Bioorg. Med. Chem. Lett., 2002, 12, 1563-1566.
65. Chordia, M.D.; Zigler, M.; Murphree, L.J.; Figler, H.; Macdonald, T.L.; Olsson, R.A.; Linden J. 6-Aryl-8H-indeno[1,2-d]thiazol-2ylamines: A1 adenosine receptor agonist allosteric enhancers having improved potency. J. Med. Chem., 2005, 48, 5131-5139.
66. Göblyös, A.; Santiago, S.N.; Pietra, D.; Mulder-Krieger, T.; von Frijtag Drabbe Künzel, J.; Brussee, J.; IJzerman, A.P. Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors: lack of effect of 2aminothiazoles as allosteric enhancers. Bioorg. Med. Chem., 2005, 13, 2079-2087.